ResearchSafe

PE 22-28 and the TREK-1 channel research

Posted by grant_climbs in Research & News - 60 points, 6 comments.

I was reading some recent papers on TREK-1 potassium channel blockers and it basically brings me back to the interest in PE 22-28. This peptide is a derivative of spadin and it is designed to block those specific channels to boost serotonergic signaling. The preclinical data suggesting it might work much faster than traditional SSRIs for neurogenesis is very interesting.

For me, the speed of action is the most fascinating part. Most antidepressant research focuses on slow changes in receptor density, but the idea of rapid synaptogenesis through TREK-1 inhibition seems like a different mechanism entirely. However, since it is still in the preclinical stage, I am very skeptical about how it will actually translate to human subjects. We do not have any established human safety data or reliable dosing protocols yet.

I am curious if anyone else is following the specific progress on spadin derivatives. Do you think the potential for rapid neuroplasticity outweighs the massive unknown risks regarding how we might alter background potassium channels in the brain? It seems like a very high risk, high reward area of research.

Comments

  • coastal_paddles: Imo you are spot on about the risks. Blocking potassium channels sounds super sketchy to me. Potassium is so fundamental for basically every cell in the body. Even if the research is just in animals right now, the jump to humans feels massive. I have been following the spadin stuff too. The speed is what caught my eye, but the lack of human data is a huge red flag. It could easily mess with other things if the targeting isnt perfect. I am curious if anyone has seen any actual toxicology studies
  • labrat_vik: Yeah, the lack of human tox data is the real kicker here, and since potassium channels are everywhere, the risk of off target effects seems pretty high. For me, any time a compound messes with electrical activity without a ton of human safety data, I tend to stay far away. It is a big jump from a mouse to a person.
  • grant_climbs: That is basically why I am hesitant. You are right about potassium channels being everywhere. If the selectivity for TREK-1 is not PERFECT, we could see issues with heart rhythm or muscle function. I agree it is a huge jump from mouse to person. I will keep watching the papers, but I will not be the first one to try it without clear human toxicology.
  • paul_j: Imagine blocking your potassium channels and just floating away like a balloon, fwiw i feel like half these people on here would try it just because a paper said it might make them feel slightly more chill, but yeah it sounds like a great way to accidentally reboot your heart or something,’s anybody actually brave or stupid enough to touch this yet?
  • grant_climbs: I am definitely not that stupid. I only track the data for now. Your point about rebooting the heart is basically why I am so skeptical. Potassium channels are too CRITICAL for cardiac stability to just experiment with based on a mouse study. I have no intention of touching this until we see actual human safety trials. I prefer to stay on the side of caution when the mechanism is this volatile.
  • grant_climbs: I agree that the lack of specificity is the main concern. If the targeting is not perfect, it could basically interfere with cardiac rhythm or muscle contraction since those rely so much on potassium flow. I have not seen any formal toxicology studies on the 22-28 derivative specifically. Most of what I find is just the older spadin papers. It is hard to find data on the electrical activity in non-neuronal cells.

Community discussion - research and educational context only. Not medical advice.